- Home
- CCD vs KALV Comparison
CCD vs KALV Comparison
Compare CCD & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCD | KALV |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.7M | 551.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCD | KALV |
|---|---|---|
| Price | $21.35 | $15.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.17 |
| AVG Volume (30 Days) | 96.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.93 | $7.30 |
| 52 Week High | $24.68 | $17.30 |
Technical Indicators
Market Signals| Indicator | CCD | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 53.17 | 52.69 |
| Support Level | $20.55 | $14.70 |
| Resistance Level | $21.80 | $17.30 |
| Average True Range (ATR) | 0.33 | 1.15 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 63.98 | 45.77 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.